The expense and laborious process involved in bringing CAR-T therapies to patients was used a key reason for the high cost of the treatments; now, the next step in the field is to find a way to speed up this process, whoever gets there first will have a big advantage.
With this in mind, Gilead has signed a deal with Sangamo Therapeutics that could be worth over $3 billion for the latter company, in a bid to strengthen its acquisition of Kite to gain a position on the market.
